文献速递湿疹皮炎与荨麻疹

克立硼罗软膏2%治疗≥45岁淤积性皮炎:完全去中心化2a期研究

Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study.
PubMed 文献 · J Am Acad Dermatol · 2024-02-08

该随机、双盲、赋形剂对照、完全去中心化的2a期研究纳入65例≥45岁无活动性溃疡的淤积性皮炎患者,克立硼罗或赋形剂每日两次治疗6周。克立硼罗耐受性良好。

要点

  • 克立硼罗2%软膏每日两次治疗6周可显著改善淤积性皮炎体征。
  • 中心皮肤科医生照片评估的疗效差异较现场非皮肤科医生评估更显著。
  • 皮肤及皮下组织不良事件为克立硼罗组常见治疗中出现的不良事件。

核心结论

  • 克立硼罗2%软膏可改善淤积性皮炎的体征和症状,且耐受性良好。

研究设计与样本

  • 随机、双盲、赋形剂对照、完全去中心化的2a期研究(NCT04091087)。
  • 65例≥45岁无活动性溃疡的淤积性皮炎患者按1:1随机接受克立硼罗或赋形剂每日两次治疗6周。
  • 主要终点为第6周基于现场评估的总体征评分较基线的百分比变化。

主要发现

  • 基于中心评估的IGA成功/改善及病灶体表面积百分比达统计学显著,现场评估未达。
  • 皮肤及皮下组织不良事件为克立硼罗组常见全因治疗中出现的不良事件。

关键数值与推荐

  • 主要终点:第6周现场评估总体征评分较基线百分比变化。

临床怎么用

  • 克立硼罗2%软膏每日两次治疗6周可作为无活动性溃疡的≥45岁淤积性皮炎患者的潜在局部治疗选择。
  • 中心皮肤科医生照片评估可用于去中心化临床研究中的疗效评价。

局限性

  • 样本量小且治疗持续时间短。
  • 现场评估非由皮肤科医生进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Crisaborole ointment, 2%, is a nonsteroidal topical phosphodiesterase 4 inhibitor approved for the treatment of mild-to-moderate atopic dermatitis. OBJECTIVE: To evaluate the efficacy and safety of crisaborole in stasis dermatitis (SD). METHODS: In this randomized, double-blind, vehicle-controlled, decentralized phase 2a study (NCT04091087), 65 participants aged ≥45 years with SD without active ulceration received crisaborole or vehicle (1:1) twice-daily for 6 weeks. The primary end point was percentage change from baseline in total sign score at week 6 based on in-person assessment. RESULTS: Crisaborole-treated participants had significantly reduced total sign score from baseline versus vehicle based on in-person (nondermatologist) assessment (-32.4% vs -18.1%, P = .0299) and central reader (dermatologists) assessment of photographs (-52.5% vs -10.3%, P = .0004). Efficacy according to success and improvement per Investigator's Global Assessment score and lesional percentage body surface area reached statistical significance based on central reader but not in-person assessments. Skin and subcutaneous tissue disorders were common all-causality treatment-emergent adverse events with crisaborole. LIMITATIONS: Small sample size and short treatment duration were key limitations. In-person assessment was not conducted by dermatologists. CONCLUSION: Crisaborole improved signs and symptoms of SD and was well tolerated. Central reader assessment represents a promising approach for siteless clinical research.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Kirsner RS, Margolis DJ, et al. Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study. J Am Acad Dermatol. 2024. PMID: 38340127. doi:10.1016/j.jaad.2023.12.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。